• Mashup Score: 0

    We advance health and well-being by promoting research and education in biological and biomedical sciences through collaborative advocacy and service to our societies and their members.

    Tweet Tweets with this article
    • Are you registered? It's free. An exciting forum for learning from experts in this fast-emerging field of #cellbiology, with implications for #cancer, #neuropathic, and #infectious diseases. Join us online next Wednesday October 4th, hosted by @FASEBorg https://t.co/nmtQap9pYA https://t.co/PyH268daMo

  • Mashup Score: 0

    The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in non-immunized patients receiving a very low dosage of ATG versus BSX as induction. Study outcomes…

    Tweet Tweets with this article
    • Induction with a very low dose of #ATG in non-immunized recipients is safe and associated with a lower rate of #BPAR and #PTD without increasing #infectious #complications in #kidneytransplant recipients https://t.co/MKZNIKlell https://t.co/jxKH52kCq4